28. Systemic amyloidosis Clinical trials / Disease details

Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-001787-22-IT (EUCTR)	02/05/2012	12/01/2012	Treatment with pomalidomide and dexamethasone for previously treated patients with AL amyloidosis.	An open-label, phase II study of Pomalidomide and Dexamethasone (PDex) for previously treated patients with AL amyloidosis - PDex	Previously treated AL amyloidosis MedDRA version: 14.1;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Product Name: pomalidomide Product Code: CC -4047 INN or Proposed INN: Pomalidomide INN or Proposed INN: DEXAMETHASONE SODIUM SULFATE	OSPEDALE POLICLINICO S. MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Italy
2	NCT00166413 (ClinicalTrials.gov)	April 2005	12/9/2005	Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis	A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis	Amyloidosis	Drug: CC -5013	Mayo Clinic	NULL	Completed	18 Years	N/A	Both	38	Phase 2	United States
3	NCT00091260 (ClinicalTrials.gov)	January 2004	7/9/2004	CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis	Multiple Myeloma	Drug: dexamethasone;Drug: lenalidomide	Vaishali Sanchorawala	Celgene Corporation	Completed	18 Years	N/A	All	82	Phase 2	United States